Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.

MLA

Uttervall, Katarina, et al. “Upfront Bortezomib, Lenalidomide, and Dexamethasone Compared to Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma.” European Journal of Haematology, vol. 103, no. 3, Sept. 2019, pp. 247–54. EBSCOhost, https://doi.org/10.1111/ejh.13280.

APA

Uttervall, K., Borg Bruchfeld, J., Gran, C., Wålinder, G., Månsson, R., Lund, J., Gahrton, G., Alici, E., & Nahi, H. (2019). Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. European Journal of Haematology, 103(3), 247–254. https://doi.org/10.1111/ejh.13280

Chicago

Uttervall, Katarina, Johanna Borg Bruchfeld, Charlotte Gran, Göran Wålinder, Robert Månsson, Johan Lund, Gösta Gahrton, Evren Alici, and Hareth Nahi. 2019. “Upfront Bortezomib, Lenalidomide, and Dexamethasone Compared to Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma.” European Journal of Haematology 103 (3): 247–54. doi:10.1111/ejh.13280.